We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
5 Relative Price Strength Options Available to Investors
U.S. markets are grappling with uncertainty as a hawkish tone from Fed Chairman Jerome Powell on rate cuts and President-elect Donald Trump’s nomination of a vaccine skeptic to lead the Department of Health and Human Services weigh on sentiment. With post-election rallies fading, investors are turning cautious. In such volatility, a relative price strength strategy — focusing on stocks outperforming their peers — offers a resilient approach to identifying winning investments while minimizing risks in unpredictable markets.
At this stage, investors would be wise to consider stocks like Rigel Pharmaceuticals, Synchrony Financial, SkyWest, Inc., Allient Inc. and Rush Street Interactive based on their relative price strength.
Relative Price Strength Strategy
Earnings growth and valuation multiples are indeed important for investors to determine a stock's ability to offer considerable returns. But these are also essential for determining whether a stock’s price performance is better than its peers or the industry average.
If a stock’s performance is lacking that of the broader groups, despite impressive earnings growth or valuation multiples, then something must be wrong.
It’s always advisable to stay away from these stocks and bet on those that are outperforming their respective industry or benchmark. This is because betting on a winner always proves to be lucrative.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals indicate room for growth and are the best ways to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Rigel Pharmaceuticals: It is a clinical-stage company dedicated to discovering and developing innovative small-molecule drugs. RIGL’s focus spans inflammatory diseases, cancer, and viral infections. The Zacks Consensus Estimate for 2024 earnings of Rigel Pharmaceuticals indicates 112.1% growth. Headquartered in South San Francisco, CA, RIGL has a VGM Score of A.
The firm has a market capitalization of $424.5 million. Rigel Pharmaceuticals beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, the average being 1,754.3%. RIGL shares have increased 157.4% in a year.
Synchrony Financial: It is one of the nation’s premier consumer financial services companies, offers a wide range of credit products. The 2024 Zacks Consensus Estimate for Stamford, CT-based SYF indicates 25.6% year-over-year earnings per share growth. Synchrony Financial has a VGM Score of A.
SYF beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, the average being 4.5%. Synchrony Financial shares have gone up 117.9% in a year.
SkyWest: It operates as a regional airline in the United States through its subsidiary SkyWest Airlines. The Zacks Consensus Estimate for 2024 earnings of SkyWest indicates 829.8% growth. Headquartered in Saint Georg, UT, SKYW has a VGM Score of B.
The firm has a market capitalization of $4.5 billion. SkyWest beat the Zacks Consensus Estimate for earnings in each of the last four quarters, the average being 79.1%. SKYW shares have gained 135% in a year.
Allient: Based in New York, the company designs, manufactures, and sells precision motion control systems and components, serving diverse global markets, including industrial, medical, vehicle, and aerospace and defense, with integrated solutions and standalone products. ALNT, with a VGM Score of B, has a current market capitalization of $408.3 million.
Notably, over the past 60 days, the Zacks Consensus Estimate for Allient’s 2024 earnings has moved up 10.9%. It beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, the average being 38.5%. ALNT shares have lost 8.7% in a year.
Rush Street Interactive: It develops and operates regulated online gaming platforms, offering real-money casino games, sports wagering, and social gaming across multiple U.S. states and international markets. The 2024 Zacks Consensus Estimate for Chicago, IL-based RSI indicates 235.7% year-over-year earnings per share growth. Rush Street Interactive has a VGM Score of B.
Rush Street Interactive beat the Zacks Consensus Estimate for earnings in each of the last four quarters, the average being 225%. RSI shares have surged 137.8% in a year.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive
For Immediate Release
Chicago, IL – November 19, 2024 – Stocks in this week’s article are Rigel Pharmaceuticals (RIGL - Free Report) , Synchrony Financial (SYF - Free Report) , SkyWest, Inc. (SKYW - Free Report) , Allient Inc. (ALNT - Free Report) and Rush Street Interactive (RSI - Free Report) .
5 Relative Price Strength Options Available to Investors
U.S. markets are grappling with uncertainty as a hawkish tone from Fed Chairman Jerome Powell on rate cuts and President-elect Donald Trump’s nomination of a vaccine skeptic to lead the Department of Health and Human Services weigh on sentiment. With post-election rallies fading, investors are turning cautious. In such volatility, a relative price strength strategy — focusing on stocks outperforming their peers — offers a resilient approach to identifying winning investments while minimizing risks in unpredictable markets.
At this stage, investors would be wise to consider stocks like Rigel Pharmaceuticals, Synchrony Financial, SkyWest, Inc., Allient Inc. and Rush Street Interactive based on their relative price strength.
Relative Price Strength Strategy
Earnings growth and valuation multiples are indeed important for investors to determine a stock's ability to offer considerable returns. But these are also essential for determining whether a stock’s price performance is better than its peers or the industry average.
If a stock’s performance is lacking that of the broader groups, despite impressive earnings growth or valuation multiples, then something must be wrong.
It’s always advisable to stay away from these stocks and bet on those that are outperforming their respective industry or benchmark. This is because betting on a winner always proves to be lucrative.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals indicate room for growth and are the best ways to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Rigel Pharmaceuticals: It is a clinical-stage company dedicated to discovering and developing innovative small-molecule drugs. RIGL’s focus spans inflammatory diseases, cancer, and viral infections. The Zacks Consensus Estimate for 2024 earnings of Rigel Pharmaceuticals indicates 112.1% growth. Headquartered in South San Francisco, CA, RIGL has a VGM Score of A.
The firm has a market capitalization of $424.5 million. Rigel Pharmaceuticals beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, the average being 1,754.3%. RIGL shares have increased 157.4% in a year.
Synchrony Financial: It is one of the nation’s premier consumer financial services companies, offers a wide range of credit products. The 2024 Zacks Consensus Estimate for Stamford, CT-based SYF indicates 25.6% year-over-year earnings per share growth. Synchrony Financial has a VGM Score of A.
SYF beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, the average being 4.5%. Synchrony Financial shares have gone up 117.9% in a year.
SkyWest: It operates as a regional airline in the United States through its subsidiary SkyWest Airlines. The Zacks Consensus Estimate for 2024 earnings of SkyWest indicates 829.8% growth. Headquartered in Saint Georg, UT, SKYW has a VGM Score of B.
The firm has a market capitalization of $4.5 billion. SkyWest beat the Zacks Consensus Estimate for earnings in each of the last four quarters, the average being 79.1%. SKYW shares have gained 135% in a year.
Allient: Based in New York, the company designs, manufactures, and sells precision motion control systems and components, serving diverse global markets, including industrial, medical, vehicle, and aerospace and defense, with integrated solutions and standalone products. ALNT, with a VGM Score of B, has a current market capitalization of $408.3 million.
Notably, over the past 60 days, the Zacks Consensus Estimate for Allient’s 2024 earnings has moved up 10.9%. It beat the Zacks Consensus Estimate for earnings in three of the last four quarters and missed in the other, the average being 38.5%. ALNT shares have lost 8.7% in a year.
Rush Street Interactive: It develops and operates regulated online gaming platforms, offering real-money casino games, sports wagering, and social gaming across multiple U.S. states and international markets. The 2024 Zacks Consensus Estimate for Chicago, IL-based RSI indicates 235.7% year-over-year earnings per share growth. Rush Street Interactive has a VGM Score of B.
Rush Street Interactive beat the Zacks Consensus Estimate for earnings in each of the last four quarters, the average being 225%. RSI shares have surged 137.8% in a year.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2371771/5-relative-price-strength-options-available-for-investors
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.